ACXP vs. LLY

In the year-to-date period, ACXP achieves a -55.77% return, which is significantly lower than LLY's -4.68% return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Acurx Pharmaceuticals, Inc. (ACXP) and Eli Lilly and Company (LLY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current ACXP Sharpe Ratio is -0.88, which is lower than the LLY Sharpe Ratio of -0.11. The chart below compares the historical Sharpe Ratios of ACXP and LLY, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

ACXP has not paid dividends to shareholders, while LLY's dividend yield for the trailing twelve months is around 0.74%.

The maximum ACXP drawdown since its inception was -96.13%, which is greater than LLY's maximum drawdown of -68.27%. Use the drawdown chart below to compare losses from any high point for ACXP and LLY. For additional features, visit the drawdowns tool.

Acurx Pharmaceuticals, Inc. (ACXP) and Eli Lilly and Company (LLY) have volatilities of 21.86% and 22.18%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Acurx Pharmaceuticals, Inc. and Eli Lilly and Company. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.